Drug Profile
Research programme: RNA interference-based therapeutics - Abbott/Dharmacon
Latest Information Update: 25 Jan 2013
Price :
$50
*
At a glance
- Originator Abbott Laboratories; Dharmacon
- Class
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 06 Jul 2006 Early research in Cancer in USA (unspecified route)